Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.

In this interview, Magdalena Corona de Lapuerta, recipient of the Jian-Jian Luan Award for Lymphoma Transplant Research, ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

SGN-CD19A demonstrated anti-tumor activity across a panel of cell lines derived from multiple B-cell lymphoma and leukemia ... that define the 'ideal' ADC and mechanisms of ADC resistance require ...

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

While the exact mechanism still needs to be elucidated ... How Could HIV-infected Macrophages Contribute to B-cell Lymphomas? HIV-infected macrophages may contribute to lymphomagenesis through ...